First-line treatment of prostate cancer by disease stage and risk classification – review article
DOI: 10.22591/magyurol.2021.4.fazekasf.163
Authors:
Fazekas Fruzsina dr.1, Maráz Anikó dr.2, Lakosi Ferenc dr.3,
Buzogány István dr.1, Beöthe Tamás dr.1
1Dél-pesti Centrumkórház, Péterfy Sándor Kórház-Rendelőintézet és Manninger Jenő Országos Traumatológiai Központ, Urológiai Osztály, Budapest (osztályvezető: Buzogány István dr.)
2Szegedi Tudományegyetem, Onkoterápiás Klinika, Szeged (igazgató: Oláh Judit dr.)
3Kaposi Mór Oktató Kórház Dr. Baka József Diagnosztikai és Onkoradiológiai Központ,Onkoradiológiai Részleg, Kaposvár (osztályvezető: Lakosi Ferenc dr.)
Summary
The treatment of prostate cancer has changed radically in the last two decades; a trend that continues to this day. In localised, low risk cases treatment can be deferred (active surveillance) and therefore adverse effects can be avoided or delayed. Curative interventions (surgery or radiotherapy) can be offered to patients with more extensive disease, thus increasing the number of patients recovered. More and more treatment steps can be offered in metastatic prostate cancer consequently increasing patient survival and quality of life. Complex and combined treatments are essential at every stage for optimal results. Appropriate management plan at first presentation can add multiple asymptomatic years and increase overall survival. Involvement of a multidisciplinary cancer care team is therefore crucial before starting any oncology treatment.